'김갑성' 기자의 전체기사
-
Ivonescimab Plus Chemotherapy Demonstrates Consistent…
[ 메디채널 김갑성 기자 ] The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 In the North American patients, the OS HR was 0.70 The HARMONi trial has already demonstrated clinically meaningful and statistically significant progression-free survival (PFS) outcomes In the HARMONi trial, clinical endpoint benefits, including OS and PFS, were consistent across Western and Asian patient populations, and these results were also in alignment with the clinical data from the HARMONi-A trial conducted in China HONG KONG, Sept. 7, 2025 -- A
- 김갑성 기자
- 2025-09-07 18:08
-
New Board, New Strategy: Home Control Taps Global Perspec…
HONG KONG, Sept. 6, 2025 -- Traditionally in Hong Kong's capital market, Home Control (1747.HK) has often been described as a "hidden gem". The company has maintained a solid financial track record with consistent dividend payouts, yet has rarely been in the market spotlight. Recently, the appointment of several new directors has drawn significant investor attention, propelling the share price to record highs since listing, with a year-to-date gain of more than tenfold. The newly appointed board members bring extensive experience and strong credentials across smart healthcare
- 김갑성 기자
- 2025-09-06 02:07
-
Huadong Medicine Announces Positive Preliminary Results…
HANGZHOU, China, Sept. 5, 2025 -- Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") today announced positive preliminary results from a Phase I study of HDM2005, an independently developed Class 1 innovative antibody–drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma (cHL). The results showed that HDM2005 demonstrated promising efficacy with a favorable safety and tolerability profile in B-NHL and cHL, which will suppo
- 김갑성 기자
- 2025-09-05 21:38
-
'CART BP pro' Opens a New Paradigm in Blood Pressure Mana…
SEOUL, South Korea, Sept. 5, 2025 -- At the European Society of Cardiology (ESC) Congress 2025, held in Madrid from August 29 to September 1, Sky Labs presented new clinical findings on CART BP pro, its cuffless, ring-type blood pressure monitor. The device demonstrated consistent accuracy even when the arm was positioned below heart level, meeting the rigorous validation requirements set by the European Society of Hypertension (ESH). The ESH recommends six validation tests for cuffless blood pressure devices, namely the static test for absolute accuracy, the device pos
- 김갑성 기자
- 2025-09-05 20:48
-
FUTUONING Sets Sail Commercially with First Prescriptions Across…
SHANGHAI, Sept. 5, 2025 -- These days, the first prescriptions of FUTUONING (fovinaciclib citrate capsules) were issued by more than ten hospitals across China, including Fudan University Shanghai Cancer Center, Cancer Hospital of the Chinese Academy of Medical Sciences, The First Affiliated Hospital Zhejiang University School of Medicine, The First Affiliated Hospital of Anhui Medical University, Shandong Cancer Hospital, Shanghai Tenth People's Hospital, Nanjing Drum Tower Hospital and The Affiliated Hospital of Qingdao University. FUTUONING, a CDK4/6 inhibitor, is indicated in combi
- 김갑성 기자
- 2025-09-05 18:12
-
Senhwa Biosciences CX-5461 Secures NCI Support to Advanc…
TAIPEI and SAN DIEGO, Sept. 5, 2025 -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has granted IND clearance for its innovative drug candidate Pidnarulex(CX-5461) ina Phase 1b/2 clinical trial in patients with B-cell lymphoma subtypes that harbors MYC gene aberrations. Given that nearly 30% of all cancers are associated with MYC oncogene overexpression, the clinical development of CX-5461 is generating significant anticipation. If the trial delivers positive resu
- 김갑성 기자
- 2025-09-05 16:46
-
Immunofoco Earns Spot on Forbes Asia 100 to Watch 2025 List…
SHANGHAI, Sept. 5, 2025 -- Immunofoco, a clinical-stage biotechnology company, focused on developing novel cell therapies for solid tumors, has been selected for the prestigious "Forbes Asia 100 to Watch 2025" list. This annual list, compiled by the editors of Forbes Asia, spotlights outstanding small companies and startups across the Asia-Pacific region that are recognized for their innovation and strong growth potential. Immunofoco stands out as one of only nine companies from Mainland China and one of two in the Biotechnology & Healthcare sector on the list, highlighti
- 김갑성 기자
- 2025-09-05 16:09
-
Intelligent perimeter protection white paper: How multi-sensi…
HANGZHOU, China, Sept. 5, 2025 -- Perimeter protection is the essential first line of defense in physical security, acting as a critical barrier against unauthorized access and safeguarding valuable assets. However, traditional perimeter security systems often struggle with false alarms, environmental interference, and costly manual verification — issues that can undermine both safety and efficiency. As threats grow in sophistication and perimeter security needs become more dynamic, organizations require smarter, more adaptive solutions that can deliver accurate detection and real-time respon
- 김갑성 기자
- 2025-09-05 10:53
-
Medidata Secures a Leader Position in Everest Group's PEAK…
Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and reducing study build timeline by up to 50% compared to the industry standard SINGAPORE, Sept. 5, 2025 -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has been recognized as a Leader in Everest Group's Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment 2025. The report assessed 19 providers based on their demonstrated success in delivering products and drivin
- 김갑성 기자
- 2025-09-05 10:00
-
Smartee and Dental Monitoring Partner to Simplify Refinement Wo…
SHANGHAI, Sept. 5, 2025 -- Smartee Denti-Technology, a leading innovator in clear aligner solutions, and Dental Monitoring, the global leader in AI-powered remote monitoring for orthodontics, today announced a new integration designed to simplify and accelerate refinement workflows for orthodontists and dental professionals. Traditionally, refinement in clear aligner treatment requires patients to visit their orthodontist's office for an intraoral scan. The scan is then submitted to Smartee to generate a new treatment plan. While precise, this process often adds extra appointme
- 김갑성 기자
- 2025-09-05 09:30
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 15:00
- Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 14:00
- From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 13:00
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
- 제2회 마나르 아부다비 출품 작가 명단 공개 00:48
- 중국-피지 어업 협력, 섬나라 경제 활력 끌어올리다 00:00
2025-10-18_SAT
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 19일 16시 40분